The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Eli Lilly and Company’s competing weight-loss drug, Zepbound (tirzepatide), could post over ... They were joined by RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and ...

The company has secured $410m in an oversubscribed Series A funding round, co-led by Forbion and General Atlantic, with contributions from investors such as RA Capital Management, OrbiMed, Logos ...

The Richmond, California-based biotech reckons that azelaprag can amplify the weight loss achieved with tirzepatide and improve ... Medicxi, Logos Capital, Octagon Capital, Piper Heartland ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Lexaria Bioscience (LEXX) provided an annual letter from CEO Richard Christopher, which read in part, “In 2024, Lexaria made the course ...

Enter GetSimpli Oral Tirzepatide, a revolutionary product that promises to transform your approach to weight loss and metabolic health. Unlike traditional weight loss methods that often involve ...

Weight-loss drugs have been rolled out by the NHS, but many are buying them through social media and online pharmacies ...